logo
logo
LIVN stock ticker logo

LivaNova PLC

NASDAQ•LIVN
CEO: Mr. Alex Shvartsburg C.M.A.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2015-10-19
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Contact Information
20 Eastbourne Terrace, London, W2 6LG, United Kingdom
44-20-3325-0660
www.livanova.com
Market Cap
$3.67B
P/E (TTM)
-15.1
23.8
Dividend Yield
--
52W High
$71.92
52W Low
$34.24
52W Range
87%
Rank51Top 71.3%
3.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$360.86M+0.00%
4-Quarter Trend

EPS

$0.57+0.00%
4-Quarter Trend

FCF

$50.20M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Growth Strong Net revenue reached $1.39B USD, increasing 10.7% versus 2024; Cardiopulmonary revenue grew 14.9% across all regions.
Segment Income Rises Cardiopulmonary segment income increased 40.9% to $108.3M USD due to revenue growth and litigation provision decrease.
Debt Obligations Reduced Total long-term debt obligations decreased 48.1% to $345.2M USD by year-end 2025 following significant repayments.

Risk Factors

Global Operations Volatility Business faces risks from global market volatility, trade restrictions, fluctuating exchange rates, and supply chain challenges.
Cybersecurity Incident Risk Failure to protect IT systems or data corruption could materially affect operations, reputation, and financial condition.
Regulatory Compliance Burden Complex, evolving global regulations, including MDR and privacy laws, require significant ongoing compliance resources and costs.
Product Liability Exposure Ongoing litigation regarding 3T Heater-Cooler device poses risk of material adverse effect on financial condition and liquidity.

Outlook

R&D Investment Strategy Commitment remains to developing technological enhancements, integrating AI capabilities, and pursuing new uses for existing products.
Liquidity Position Stable Current liquidity sources are deemed sufficient to fund operations over the next twelve months, optimizing capital structure as needed.
Tax Law Monitoring Company actively monitors evolving global tax legislation, including Pillar Two, to assess potential impacts on effective tax rate.
Talent Retention Focus Strategy emphasizes attracting and retaining key talent through competitive compensation, development programs, and rewarding work environment.

Peer Comparison

Revenue (TTM)

SGRY stock ticker logoSGRY
$3.31B
+6.2%
LIVN stock ticker logoLIVN
$1.39B
+10.7%
PBH stock ticker logoPBH
$1.10B
-1.3%

Gross Margin (Latest Quarter)

IDYA stock ticker logoIDYA
89.0%
+0.0pp
APLS stock ticker logoAPLS
85.1%
+11.7pp
LIVN stock ticker logoLIVN
66.4%
-2.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CNTA$5.92B-27.2-50.7%1.1%
SRRK$5.74B-15.2-145.9%26.9%
CDTX$5.61B-18.6-60.1%0.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.4%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:May 5, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data